{"id":"5033ec4a-ee77-5215-9ac3-a4962536d754","stable_key":"e69ef6a0-0e23-5eac-aca1-cf333781b962:ino-gdm-2025","predicate":"did_not_significantly_reduce","statement":"In MYPP, the gestational-diabetes/preeclampsia/preterm-birth composite occurred in 25.0% versus 26.8% (RR 0.93, 95% CI 0.68–1.28; P=0.67).","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"a3779aa9-23f4-5f88-aa02-a705e0380d2d","mechanism_event_label":"The larger blinded PCOS-pregnancy trial did not demonstrate a reduction in its main complication outcome.","subject":{"id":"50afe95c-f542-5511-ba8b-c2ff2b037977","slug":"myo-inositol","display_name":"Myo-inositol","entity_type_key":"small_molecule"},"object":{"id":"801b9417-a2df-5291-89ba-19b7a3e67d09","slug":"pregnancy-complication-composite","display_name":"Gestational diabetes, preeclampsia or preterm birth composite","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"a3779aa9-23f4-5f88-aa02-a705e0380d2d","stable_key":"e69ef6a0-0e23-5eac-aca1-cf333781b962:ino-gdm-2025-event","event_type":"observed_intervention","label":"The larger blinded PCOS-pregnancy trial did not demonstrate a reduction in its main complication outcome.","description":"In MYPP, the gestational-diabetes/preeclampsia/preterm-birth composite occurred in 25.0% versus 26.8% (RR 0.93, 95% CI 0.68–1.28; P=0.67).","status":"provisional","compartment":null,"participants":[{"entity":{"id":"d322bfef-5135-599f-82e6-0aa58748dc8b","slug":"folic-acid","display_name":"Folic acid","entity_type_key":"small_molecule"},"role":"both_groups","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"50afe95c-f542-5511-ba8b-c2ff2b037977","slug":"myo-inositol","display_name":"Myo-inositol","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"801b9417-a2df-5291-89ba-19b7a3e67d09","slug":"pregnancy-complication-composite","display_name":"Gestational diabetes, preeclampsia or preterm birth composite","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/inositol-research/40920401.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"f72221b219fbb1cae0af2c44b123ab1e95c74e0ba9c10f75ed601720b96248a0\", \"start_char\": 0, \"end_char\": 1949, \"text_sha256\": \"f72221b219fbb1cae0af2c44b123ab1e95c74e0ba9c10f75ed601720b96248a0\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"MYPP double-blind multicenter randomized trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Myo-inositol 2 g plus folic acid 0.2 mg twice daily versus matching folic acid control until delivery","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A larger null result for a prespecified composite in PCOS pregnancy; not the same population or endpoint as the 2013 trial. Confidence limits permit benefit or harm of varying sizes.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Inositol research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"inositol","display_name":"Inositol (stereoisomer family)","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The larger blinded PCOS-pregnancy trial did not demonstrate a reduction in its main complication outcome.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ino-p40920401] Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial. (2025). https://pubmed.ncbi.nlm.nih.gov/40920401/ DOI: 10.1001/jama.2025.13668","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"464 pregnant individuals with PCOS at 13 Dutch hospitals","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"e693a081-848f-52ac-9e41-0520694d99bd","evidence_kind":"source_excerpt","locator":"Lines 1341-1352","start_line":1341,"end_line":1352,"excerpt":"### ino-gdm-2025\nIn MYPP, the gestational-diabetes/preeclampsia/preterm-birth composite occurred in 25.0% versus 26.8% (RR 0.93, 95% CI 0.68–1.28; P=0.67).\nCondition category: normal\nnutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The larger blinded PCOS-pregnancy trial did not demonstrate a reduction in its main complication outcome.\norganism: Homo sapiens\ntissue_or_cell_type: 464 pregnant individuals with PCOS at 13 Dutch hospitals\nexperimental_model: MYPP double-blind multicenter randomized trial\nlimitations: A larger null result for a prespecified composite in PCOS pregnancy; not the same population or endpoint as the 2013 trial. Confidence limits permit benefit or harm of varying sizes.\nexposure: Myo-inositol 2 g plus folic acid 0.2 mg twice daily versus matching folic acid control until delivery\nevidence_span: {\"source_cache\": \"artifacts/inositol-research/40920401.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"f72221b219fbb1cae0af2c44b123ab1e95c74e0ba9c10f75ed601720b96248a0\", \"start_char\": 0, \"end_char\": 1949, \"text_sha256\": \"f72221b219fbb1cae0af2c44b123ab1e95c74e0ba9c10f75ed601720b96248a0\"}\n[ino-p40920401] Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial. (2025). https://pubmed.ncbi.nlm.nih.gov/40920401/ DOI: 10.1001/jama.2025.13668","model_system":"MYPP double-blind multicenter randomized trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ino-p40920401] Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial. (2025). https://pubmed.ncbi.nlm.nih.gov/40920401/ DOI: 10.1001/jama.2025.13668","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d590c659-b774-50e6-9f1d-aff61d5f7c9c","stable_key":"import-e69ef6a0-0e23-5eac-aca1-cf333781b962","title":"Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"f7adbcedad647d5f8a3cc9e46bfa515e83c508be9c2a4e9d59c5f5dfb0667d53","revision_id":"a82d187c-60fb-52d1-8482-eadb92860f33","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}